

**28 February 2020**

## **Full Year Results Investor Briefing - New Time**

Sydney, Australia, 28 February 2020: Australian medical technology company, Next Science Limited (ASX:NXS), confirms that it intends to release its results for the full year ended 31 December 2019 on Friday 28 February 2020.

Due to technical difficulties, a new time has been set for the investor conference call of 11.30am (AEDT) today, Friday 28 February 2020.

Next Science's Managing Director, Judith Mitchell, will host an investor conference call and webcast at 11.30am (AEDT) on 28 February 2020 to discuss the results. The briefing is expected to last approximately 45 minutes inclusive of question time.

To pre-register for the call, please use the following link:

<https://s1.c-conf.com/diamondpass/10003808-invite.html>

To register to participate via webcast, please use the following link:

<https://webcast.openbriefing.com/5812/>

This announcement has been authorised to be given to ASX by Next Science's Managing Director.

---ENDS---

**For further information, please contact:**

**Judith Mitchell, Managing Director**

Phone: +61 2 8607 5124

Email: [investorqueries@nextscience.com](mailto:investorqueries@nextscience.com)

**Michael Brown**

Phone: +61 400 248 080

Email: [mbrown@pegasusadvisory.com.au](mailto:mbrown@pegasusadvisory.com.au)

## **About Next Science**

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and continued commercialisation of its proprietary Xbio technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. For further information visit: [www.nextscience.com](http://www.nextscience.com).